Cite
HARVARD Citation
Arend, R. et al. (n.d.). 76 Patients (PTS) with recurrent gynecologic cancer whose tumors have activating wnt pathway mutations respond better to DKN-01, a DICKKOPF-1 (DKK1) inhibitor. International journal of gynecological cancer. pp. A40-A41. [Online].